[10] Alzahrani, W.S., Bahkali, S.A., Alharthy, R.F., Alsabban, A.S., (2025)
In 2023, the FDA launched an investigation after GLP-1 agonist users started reporting thoughts of suicide as of January 2024, it hadnt found anything to confirm the connection, but it also said it couldnt yet rule it out, meaning its possible the drugs could cause mental health issues for some people, rather than treating or preventing them
Curr Rev Musculoskelet Med 18 , 611619 (2025)
See GLP-1 use while breastfeeding for context on why
While these results are highly encouraging, Retatrutide is undergoing further trials, such as TRIUMPH-2 and TRIUMPH-3
De esta manera, los agonistas GLP-1, a diferencia de otros medicamentos para el tratamiento de la diabetes mellitus, primero demostraron que podan ayudar a este grupo de pacientes a perder peso, y luego demostraron esta misma habilidad en la poblacin general